04:53 AM EST, 11/04/2026 (MT Newswires) -- Egetis Therapeutics (EGTX.ST) and its subsidiary Rare Thyroid Therapeutics International, or RTTI, agreed to sell the company's Rare Pediatric Disease Priority Review Voucher issued by the US Food and Drug Administration for gross proceeds of $190 million. The commercial-stage pharmaceutical company received the voucher in September following the US FDA's approval of Emcitate, or tiratricol, a medicine used to treat peripheral thyrotoxicosis for adult and pediatric patients with monocarboxylate transporter 8 deficiency, according to a Wednesday release. Upon closing of the newly signed definitive asset purchase agreement, subject to customary closing conditions, former owners of RTTI will receive 50% of the voucher's net proceeds as an earnout tied to the company's 2020 acquisition of Emcitate.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.